L’avez-vous remarqué? L’ASSM est sur LinkedIn

The Lausanne-based company HAYA Therapeutics, featured in the Technology Outlook showcase “The cryptic messages of our genome”, has reached two significant milestones in quick succession: the first cohort of participants has been dosed in a Phase 1 clinical trial of its lead candidate HTX-001, and the company has been named a “Disruptive Pioneer” in the 2026 Global Pharmaceutical Innovation and Invention Index published by IDEA Pharma. These developments underscore the relevance of the technology identified by SATW’s foresight activities.

Technopark Zurich normally belongs to start-ups. But on 27 March 2026, lawyers, administrative experts, researchers and digital activists took over: The Law & Tech Lab at the University of St. Gallen hosted the third AI conference. The key question: How should artificial intelligence be regulated in Switzerland - and when is the right time to do so?

Des systèmes de surveillance digitale sont de plus en plus souvent utilisés dans les hôpitaux et dans les soins de longue durée. Ils promettent un gain de sécurité et d’efficacité, ainsi qu’une aide à la prise en charge. En même temps, ils soulèvent des questions médico-éthiques et juridiques fondamentales. La Commission Centrale d’Éthique (CCE) de l’ASSM prend position à ce sujet.